Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 601 - 650 out of 50,954

Document Document Title
WO/2019/165159A1
Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need t...  
WO/2019/154416A1
The present disclosure provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein R1 and R2 manufacturing the compounds of the disclosure, and its therapeutic uses. The present disclosure further provides ...  
WO/2019/133770A3
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the en...  
WO/2019/154237A1
The present invention relates to a co-crystal of calcifediol and vitamin D3, a preparation method therefor and use thereof. In the co-crystal, the molar ratio of calcifediol to vitamin D3 is 1: 1. The co-crystal of calcifediol and vitami...  
WO/2019/156861A1
The present invention provides a compound of Formula I: wherein R1 is methyl, ethyl or cyclopropyl; R2 is hydrogen, methyl, or ethyl; R3 is methyl or AA; and R4 is C2-C4 alkyl, BB; or a pharmaceutically acceptable salt thereof; for use a...  
WO/2019/153325A1
The present invention discloses the application of an artemisinin derivative in the preparation of a medicament for preventing and treating type 2 diabetes and complications thereof, and a pharmaceutical composition containing the artemi...  
WO/2019/156199A1
The present invention addresses the problem of providing a novel drug for the prevention of autoimmune diseases, the suppression of the progression of the symptoms of autoimmune diseases, the suppression of the recurrence of autoimmune d...  
WO/2019/157417A1
Disclosed are compounds of formulas (I)-(IX) for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, wherein R1-R8, X, Y, Z, X', Y', Z', and A are as defined her...  
WO/2019/155336A1
A method for reducing blood pressure or treating renal or kidney disease in a companion animal, the method comprising orally administering a composition comprising a therapeutically effective amount of medium chain triglycerides to the c...  
WO/2019/157056A1
Provided are methods for the treatment of classic Fabry disease in a patient. Certain methods comprise administering to the patient about 123 mg free base equivalent of migalastat for reducing kidney globotriaosylceramide, stabilizing re...  
WO/2019/156251A1
The present invention provides a combination of: (1) a composition containing a living bacterium of Bacteroides vulgatus isolated from nature; and (2) a composition containing a living bacterium of Bacteroides dorei isolated from nature.  
WO/2019/154161A1
The present application relates to a pharmaceutical composition for treating male diseases. The pharmaceutical composition comprises the following component in parts by mass: 10-30 parts of a hot water extract of Maca, 10-30 parts of a h...  
WO/2019/150004A1
The present invention relates to a health beneficial composition for preventing and treating canine gastrointestinal and urinary tract disorders. The invention further relates also to a process for the manufacture of the health promoting...  
WO/2019/151883A1
The invention relates to a novel use of benzazepine, benzoxazepine, benzothiazepine-N-acetic acid and phosphono-substituted benzazepinone derivatives having both neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP), and ...  
WO/2019/152416A1
Provided herein are compounds of Formula (I) and their salts, and compositions comprising such compounds that are useful for increasing the amount of NAD+ in cells. Also disclosed are methods of using the disclosed compounds and composit...  
WO/2019/149946A1
The present invention concerns therapeutics for autoimmune diseases and provides removal of inflammation-causing autoantibodies. In order to target the disease in the most efficient manner, a nanoconjugate complex is provided, comprising...  
WO/2019/146621A1
Provided is a medicinal composition for treating diseases associated with an increase in the expression level of periostin or a change in a periostin splicing variant, said medicinal composition being characterized by comprising, as an a...  
WO/2019/091434A9
Applications of an adenosine receptor agonist in the preparation of drugs for treating uresis dysfunctions of bladders of mammals, and a method for evaluating the adenosine receptor agonist in regulation of uresis dysfunctions of the bla...  
WO/2019/145546A1
Thus, the present invention provides a method of producing a composition in powder form comprising the following steps (a) to (c): (a) providing highly dispersed silica particles, hydrophobic silica particles, and a cationic surfactant; ...  
WO/2019/141009A1
Disclosed are a compound and a pharmaceutically acceptable salt thereof, which can be used, by means of a chemical small molecule which targets both UHRF1 and HDAC1, or a pharmaceutically acceptable salt thereof, as corresponding inhibit...  
WO/2019/091433A9
The present invention provides applications of an L-type voltage-gated calcium channel agonist in the preparation of drugs for treating uresis dysfunctions of bladders of mammals, and a method for evaluating the L-type voltage-gated calc...  
WO/2019/142941A1
Provided is a method of producing, by means of a simple drying operation, high-purity ferric citrate which retains a high specific surface area while having a reduced water soluble organic solvent content. This method of producing ferric...  
WO/2019/137922A1
The present invention relates to modulators of complex 1 protein q (C1q) that preferably mimic and/or stabilize the interaction of inhibitor apolipoprotein-E (ApoE) with C1q, and their uses in the prevention or treatment of C1q-related d...  
WO/2019/106578A3
The present invention relates to anti-polyomavirus antibodies, antibody fragments, and their uses for the prevention and treatment of BK or JC virus infection and associated diseases.  
WO/2019/134680A1
The present invention relates to a fused ring compound having the structure represented by formula I, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a solvate thereof, or a prodrug molecule thereof. The novel fused r...  
WO/2019/134159A1
A rectal mucosal administration preparation of Pulsatilla chinensis (Bge.) Regel saponin B4, comprising Pulsatilla chinensis (Bge.) Regel saponin B4 and a pharmaceutically acceptable substrate; the rectal mucosal administration preparati...  
WO/2019/136158A1
The disclosure provides peptide products comprising a peptide covalently attached to a surfactant moiety which have improved properties, including increased duration of action and bioavailability. The peptide products are useful for trea...  
WO/2019/134482A1
Provided are the uses of a protein in preparing a drug for preventing and treating kidney disease, specifically a sDDS1 protein used in preparing a drug for preventing and treating kidney disease. The sDSS1 can effectively bind to advanc...  
WO/2019/133022A1
A method for preventing, treating and/or improving a prostatic disease or disorder associated with epithelial hyperplasia and/or fibrosis, comprising: administering an effective amount of a multikinase inhibitor to a subject in need ther...  
WO/2019/132021A1
The present invention addresses the problem of providing a pharmaceutical composition capable of significantly inhibiting ABH8 gene expression. Provided is a pharmaceutical composition that includes: a liposome containing a cationic lipi...  
WO/2019/133950A1
Methods and compositions for the treatment and prevention of posterior capsular opacification are provided. The methods include administering a therapeutically effective amount of a Smad7 protein construct to a subject suffering from or ...  
WO/2019/131902A1
Provided are: a therapeutic agent for fecal incontinence; and a therapeutic agent for stress urinary incontinence, which is reduced in adverse side effects including an effect to induce body weight loss. Provided are: a therapeutic agent...  
WO/2019/129120A1
Disclosed herein is tolcapone as an FTO inhibitor for use in reducing food intake or appetite, reducing weight gain, promoting weight loss, reducing blood glucose, reducing serum LDL, cholesterol, LDL-c, or triglycerides, for use in prev...  
WO/2019/129310A1
Disclosed are a deuterated elagolix derivative, a pharmaceutical composition, and uses thereof. The structure of the deuterated elagolix derivative of the present invention is as shown in formula (X). The deuterated elagolix derivative a...  
WO/2019/124363A1
The present invention provides a pentosan polysulfate having an uronic acid content of 7.0-15.0 mass% and an acetyl group content of 0-2.0 mass% or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate ther...  
WO/2019/124507A1
[Problem] To provide a novel therapeutic agent for nocturnal pollakiuria. [Solution] A therapeutic agent for nocturnal pollakiuria which contains, as an active ingredient, (6S)-N-[4-({(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin- 2-yl...  
WO/2019/122051A1
The present invention relates to a formulation comprising hidrosmin characterized by a modified release rate suitable for once-daily administration.The use of said composition in the prevention or treatment of a disease selected from chr...  
WO/2019/120296A1
The present invention relates to heterocyclic compounds as arginase inhibitors, in particular to a compound represented by Formula (I), or a pharmaceutically acceptable salt, stereoisomer or tautomer, or prodrug thereof and a pharmaceuti...  
WO/2019/124757A1
The present invention relates to a composition for prevention, treatment, or amelioration of prostate disease which comprises extracts of Acanthopanacis Cortex, Phragmitis Rhizoma, and Pinus densiflora as active ingredients. A combined e...  
WO/2018/132268A8
The present disclosure provides pharmaceutical agents, including those of the formula:(I) wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceu...  
WO/2019/117116A1
The present invention addresses the problem of providing a pharmaceutical composition for treatment of a variety of conditions accompanied by renal dysfunction. Renal dysfunction is improved by a pharmaceutical composition that comprises...  
WO/2019/113642A1
The invention relates to an inhibitor of Factor XII (FXII) for use in treating or preventing chronic kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or a...  
WO/2019/114541A1
The present invention relates to the field of medicine, and particularly relates to multiple crystal forms of the compounds of formula (I), a preparation method therefor, pharmaceutical preparations and pharmaceutical compositions contai...  
WO/2019/114543A1
The present application relates to the field of medicine, and in particular, to a crystal form of a compound as represented by formula (I), a method for preparing the crystal form, a pharmaceutical composition comprising the crystal form...  
WO/2019/117654A1
The present invention provides probiotics for inhibiting and preventing the progression of renal diseases and a composition for inhibiting and preventing the progression of renal diseases comprising the same; and to novel a Lactobacillus...  
WO/2019/111960A1
The present invention stabilizes either amorphous solifenacin or a salt thereof. Provided as an embodiment of the present invention is a package containing both a drug including amorphous solifenacin or a pharmaceutically acceptable salt...  
WO/2019/109576A1
The present invention discloses a novel use of benzopyran compound, preparation of benzopyrone hamaudol and sec-O-Glucosylhamaudol, and an extract containing a rich benzopyran lactone, a preparation method, and a medical use thereof. The...  
WO/2019/112984A1
The present disclosure provides methods of treating paroxysmal nocturnal hemoglobinuria (PNH) in subjects with varying exposure to eculizumab by administering R50G0. The methods include methods of switching subjects from treatment with e...  
WO/2018/125983A8
The present invention is related to a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of aminocarboxymuc...  
WO/2019/109802A1
The present invention provides a compound of formula (A), a crystal form thereof, and a preparation of the same. The present invention also provides a pharmaceutical composition comprising the compound of formula (A) and a method of trea...  

Matches 601 - 650 out of 50,954